RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the Company’s President and Chief Executive Officer, Mark J. Ahn, Ph.D., will present a corporate overview to include the company’s recent announcement of their intent to acquire Apthera at BioCentury’s Future Leaders Conference on Friday, April 15, 2011 at 9:00 a.m. ET, at the Millennium Broadway Hotel & Conference Center in New York City.
The acquisition provides RXi with a late stage product candidate, NeuVax™, a peptide-based immunotherapy for low-to-intermediate HER2+ breast cancer, not eligible for Herceptin®, which is expected to enter Phase III clinical trials in the first half of 2012. The Company’s first RNAi product, RXI-109 which targets CTGF (connective tissue growth factor) for anti-scarring, remains on track for an investigational new drug (IND) application filing this year.
A live webcast of the presentation will be available from the “Investor Relations” section of the Company's website, www.rxipharma.com. A replay of the presentation will be available for 30 days.
About RXi Pharmaceuticals CorporationRXi Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies. Based on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi’s first RNAi product candidate, RXI-109 which targets CTGF (connective tissue growth factor), is scheduled to commence human clinical trials in anti-scarring in early 2012. RXi recently accelerated its product development focus with the acquisition of NeuVax™ which is slated to commence Phase III clinical trials in low-to-intermediate HER2+ breast cancer patients, not eligible for Herceptin®, in the first half of 2012. For more information please visit us at www.rxipharma.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV